SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is experiencing a major surge following a significant earnings beat that showcased triple-digit revenue growth and a record backlog, fueling intense community debate over its aggressive AI infrastructure spending. Investors are actively split between those betting on long-term growth and others cautioning that heavy debt and cash burn remain major risks.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending after the company delivered a significant earnings beat and provided robust fiscal year guidance that surpassed market expectations, driving intense debate among investors regarding its current valuation. While the community is split between bullish sentiment fueled by record order backlogs and skeptical concerns regarding management's communication style and historical controversies, many are actively monitoring for a potential short squeeze.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors aggressively monitor the highly anticipated 80th event trigger for its REGAL Phase 3 clinical trial, with community sentiment sharply divided between buyout speculation and skepticism over the extended trial timeline. The company's recent filing highlighting strong cash reserves, minimal dilution, and expanded preclinical work in pancreatic cancer has intensified community debate, as traders weigh these bullish fundamentals against the binary risks of an imminent final analysis.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

Investors in United States Antimony (UAMY) are reacting to a significant decline in revenue guidance for the year, largely attributed to volatile antimony market prices and shifting delivery timelines. Despite the bearish sentiment and active short-selling pressure, some market participants remain optimistic, viewing current levels as a long-term accumulation opportunity supported by the company's status as a domestic critical minerals supplier and potential future government contracts.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Firefly Aerospace is seeing heightened community discussion as investors weigh the stock's recent price volatility against its strategic role in government contracts and the broader space sector. While retail traders are closely watching upcoming earnings and potential partnerships, sentiment remains divided between those betting on long-term growth and others concerned by the stock's recent performance compared to sector peers.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing elevated volatility as investors weigh strong earnings and data center demand against sector-wide concerns, including potential trade restrictions on optical components. The community remains divided, with many traders actively discussing the stock's long-term growth prospects as a photonics leader versus the risk of a technical correction.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is experiencing heightened volatility and strong community interest following solid earnings results, with investors actively discussing potential capacity constraints as a key catalyst for long-term growth. The community remains largely bullish, focusing on the company's manufacturing expansion and its strategic positioning within the defense, space, and AI infrastructure sectors, often comparing its potential to past high-growth trajectories.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA Group is trending following a double beat on quarterly earnings and revenue that exceeded analyst estimates, fueled by strong guest traffic and consistent same-restaurant sales growth. While the community is actively debating the stock's high valuation relative to its peers, many investors are focused on the brand's rapid unit expansion and its potential to become a dominant national fast-casual leader.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors weigh explosive demand for AI infrastructure against concerns over high capital expenditures and dilution risks, with the community closely tracking upcoming earnings for validation. The stock remains a focal point for intense debate, as market participants actively bet on a potential short squeeze while monitoring the influence of high-profile short-sellers and institutional stake-building.

NextNav, Inc. engages in development of positioning, navigation, and timing solutions. Its products include NextNav Pinnacle, NextNav 3D, and NextNav TerraPoiNT. The company was founded by Ganesh Pattabiraman and Arun Raghupathy in May 2021 and is headquartered in Reston, VA.

NextNav Inc

NextNav is trending as investors react to legislative efforts attempting to block FCC spectrum reconfigurations, sparking intense debate over the company's regulatory path. The community remains focused on the potential for imminent FCC approval and the high strategic value of the company's spectrum assets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dr. Reddys Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion, in the United States

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a generic equivalent of Bridion, in the...

Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky

Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky PR Newswire NEW YORK, July 31, 2026 Investigation focuses on RDY losses after Dr. Reddy's disclosed a 2.4 billion provision tied to...

RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddys Laboratories (RDY)

RDY shareholders saw Dr. Reddys Laboratories (NYSE: RDY) shares fall approximately 9% on July 22, 2026, after Q1 FY27 results included a 2.4 billion provision tied to out-of-spec semaglutide batches while FY27 margin commentary remained in focus. Investors who lost money on RDY after that provision...

RDY SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Dr. Reddy's Laboratories

RDY SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Dr. Reddy's Laboratories RDY SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Dr. Reddy's Laboratories PR Newswire NEW YORK, July 27, 2026 RDY...

Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY)

Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY) Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY) PR Newswire...

Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down

RDY's fiscal Q1 earnings and revenues miss estimates as weaker North America generics sales hurt results, sending shares down 9%.

Dr. Reddy's Laboratories Q1 Net Profit Drops As Revenue Slips, Expenses Climb

(RTTNews) - Dr. Reddy's Laboratories Limited (RDY, 500124, DRREDDY), a major Indian pharmaceutical company, on Thursday posted a decline in net income for the first quarter, hurt by decreased revenue and increased expenses...

Full Transcript: Dr Reddy's Laboratories Q4 2026 Earnings Call

Dr Reddy's Laboratories (NYSE:RDY) released fourth-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below.
Benzinga APIs provide real-time access to earnings callread more...

Dr. Reddys Laboratories Limited Announces Filing of Annual Report on Form 20-F

Dr. Reddys Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as Dr. Reddys) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial...

Dr. Reddys Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif, in the United States

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the United States, expanding its oncology portfolio and...

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment refers to the manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Dr. Reddy`s Laboratories Ltd. - ADR

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$0.10	--	--	N/A
Q1 '26	$0.09	$0.06	-39.89%	MISSED
Q4 '25	$0.09	$0.03	-70.61%	MISSED
Q3 '25	$0.15	$0.16	2.44%	BEAT
Q2 '25	$0.19	$0.20	1.99%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings